Metagenomi, Inc. Hits New 52-Week Low at $1.14 Amid Declining Performance

Metagenomi, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.14 as of June 15, 2026. This significant decline highlights the company's challenging performance over the past year, with a staggering 81.83% drop compared to the S&P 500's gain of 26.39%. The company's financial metrics reflect ongoing difficulties, including a negative return on equity of -54.59% and a debt-to-equity ratio of -0.98. Metagenomi has reported negative results for five consecutive quarters, with its return on capital employed (ROCE) hitting a low of -49.02%. Additionally, raw material costs have surged by 104.78% year-over-year, further straining the company's financial health. With a market capitalization of USD 50 million, Metagenomi's stock is trading at a price-to-book ratio of 0.31, indicating potential undervaluation relative to its assets. However, the overall performance metrics suggest a challenging environment for the company as it navigates through these financial hurdles.